Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
Web
NewsPlease enter a web search for web results.
News
WebDualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
7+ hour, 27+ min ago (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...
Formosa Pharmaceuticals Files European CTA for TSY-110, Potential First Kadcyla Biosimilar in Regulated Markets
1+ hour, 16+ min ago (86+ words) 31 August 2026 | Monday | News Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared…...
The Accidental Gerotherapeutic
17+ hour, 15+ min ago (773+ words) 30 August 2026 | Sunday | Analysis Figure 1. Endpoint coverage map: where the incretin class has outcome evidence, and where it does not. Seventeen endpoints across three bands, scored against five evidence tiers. Everything above the dashed line is an organ disease endpoint measured…...
The Biological Age Business
4+ day, 19+ hour ago (577+ words) 26 August 2026 | Wednesday | Analysis Figure 1. Regulatory classification of biological age test categories against market, as at 17 August 2026. Cells record the published instrument in force, not enforcement practice. Anyone with a view has until that Friday evening to put it on the…...
ASTRI, Saint Francis University Partner to Advance AI-Enabled Biomaterials and Digital Health
5+ day, 1+ hour ago (215+ words) 26 August 2026 | Wednesday | News Ir Dr Ted Suen, Chief Executive Officer of ASTRI (left) and Professor Stephen Cheung Yan-leung, President of Saint Francis University (right), sign a Memorandum of Understanding today (24 August) establishing a strategic partnership to advance research and development…...
Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours
6+ day, 19+ hour ago (742+ words) BioPharma APAC - Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours 24 August 2026 | Monday | News Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Collaborative Research Agreement…...
Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension
6+ day, 19+ hour ago (721+ words) BioPharma APAC - Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension 24 August 2026 | Monday | News Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the first two…...
South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal
6+ day, 19+ hour ago (260+ words) 24 August 2026 | Monday | News Hanmi Pharm announced that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing, and commercialization of Hanmi's novel metabolic treatment candidate, HM17321 (UCN2), for obesity and associated conditions…...
Lōkahi Therapeutics Expands ai² Futures Lab Collaboration with University of Georgia
1+ week, 7+ hour ago (133+ words) 24 August 2026 | Monday | News During its first year, the ai² Futures Lab™ engaged 64 students and identified more than 45 potential acquisition assets. Several of these advanced into active pipeline discussions, demonstrating how the program expands Lōkahi’s sourcing reach and analytical capacity while supporting…...
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
1+ week, 1+ hour ago (172+ words) 24 August 2026 | Monday | News AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline. B7-H3 is highly expressed in a broad…...